Latest APRE reports update at 2024-03-26: 2023 ∙ 2022 ∙ 2021

Aprea Therapeutics APRE

$ 5.35 -1.83%

Aprea Therapeutics Financial Statements 2011-2024 | APRE

Annual Financial Statements Aprea Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	21.4 M	7.49 M	3.05 M	5.2 M	223 M	-	-	-	-	-	-	-	-
Shares	3.62 M	1.66 M	1.06 M	1.06 M	6 M	-	-	-	-	-	-	-	-
Historical Prices	5.92	4.52	2.87	4.92	45.9	-	-	-	-	-	-	-	-
Net Income	-14.3 M	-113 M	-37.1 M	-53.5 M	-28.1 M	-15.5 M	-15.2 M	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-15.5 M	-113 M	-37.4 M	-	-	-	-	-	-	-	-	-	-
Interest Expense	1.19 M	730 K	319 K	-668 K	1.48 M	961 K	662 K	-	-	-	-	-	-
EBITDA	-15.5 M	-113 M	-37.4 M	28.8 K	-29.4 M	-16.5 M	-16.5 M	-	-	-	-	-	-
Operating Expenses	16.1 M	113 M	37.4 M	52.8 M	29.5 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	8.43 M	21 M	13.6 M	14.9 M	8.59 M	2.29 M	2.46 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Aprea Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	3.74 M	3.73 M	3.26 M	2.66 M	1.73 M	1.13 M	1.1 M	21.9 M	21.2 M	21.2 M	21.2 M	21.2 M	21.2 M	21.1 M	21.1 M	21 M	1.18 M	1.18 M	1.17 M	1.16 M	1.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.2 M	-3.26 M	-4.38 M	-	-4.02 M	-98.3 M	-7.94 M	-	-9.45 M	-10.3 M	-9.67 M	-	-12.3 M	-16.4 M	-9.4 M	-	-6.25 M	-5.26 M	-3.48 M	-	-3.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-3.52 M	-3.65 M	-	-	-4.2 M	-98.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	318 K	393 K	243 K	-	175 K	207 K	138 K	-	-21.9 K	-253 K	521 K	-	-83.8 K	-1.89 M	2.47 M	-	969 K	676 K	933 K	-	-208 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	410	-	-4.19 M	-98.5 M	2.94 K	-	9.86 K	6.72 K	3.59 K	-	12.2 K	7.87 K	3.81 K	-	8.85 K	4.74 K	2.14 K	-	6.52 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	3.84 M	3.9 M	4.62 M	-	4.2 M	98.5 M	8.07 M	-	9.43 M	10 M	10.2 M	-	12.2 M	14.5 M	11.9 M	-	7.22 M	5.94 M	4.41 M	-	2.93 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	1.72 M	1.7 M	3.37 M	-	3.08 M	15.6 M	3.99 M	-	3.41 M	3.34 M	3.43 M	-	3.47 M	3.79 M	2.78 M	-	2.31 M	1.62 M	729 K	-	624 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency